predisposing factors for the development of cancer in humans. 2,3 A recent study involving 44 000 pairs of Scandinavian twins suggested that environmental factors are paramount contributors in cancer development. 4 The human body is well equipped with both immune and nonimmune anticarcinogenic mechanisms for fighting cancer. Natural killer (NK) lymphocytes play an important role in inhibiting tumor growth and metastases. 5 Many studies implicate oxidative stress in precipitating the 3 steps of carcinogenesis, that is, its initiation, promotion, and progression. 6 Free radicals and reactive oxygen species (ROS) generated by environmental carcinogens, or by metabolic alterations, cause DNA damage and genetic instability. [6] [7] [8] DNA damage induced by oxidative stress is the major contributor to the development of malignancy. It is wellknown that natural antioxidant defenses are active in counteracting the production of free radicals and the molecular damage inflicted by them on DNA and other C ancer is a major health problem in industrialized and developing countries. Most diagnoses of cancer occur in people more than 55 years of age, with prostate cancer being the leading type of cancer in males followed by lung cancer. In females, breast and colon cancers are the leading types of cancer. 1 Many etiological factors, including genetic, environmental, dietary, hormonal, as well as aging, the immune status, or presence of medical or psychiatric illnesses have all been suggested as Melatonin is a phylogenetically well-preserved molecule with diverse physiological functions. In addition to its well-known regulatory control of the sleep/wake cycle, as well as circadian rhythms generally, melatonin is involved in immunomodulation, hematopoiesis, and antioxidative processes. Recent human and animal studies have now shown that melatonin also has important oncostatic properties. Both at physiological and pharmacological doses melatonin exerts growth inhibitory effects on breast cancer cell lines. In hepatomas, through its activation of MT 1 and MT 2 receptors, melatonin inhibits linoleic acid uptake, thereby preventing the formation of the mitogenic metabolite 1,3-hydroxyoctadecadienoic acid. In animal model studies, melatonin has been shown to have preventative action against nitrosodiethylamine (NDEA)-induced liver cancer. Melatonin also inhibits the growth of prostate tumors via activation of MT 1 receptors thereby inducing translocation of the androgen receptor to the cytoplasm and inhibition of the effect of endogenous androgens. There is abundant evidence indicating that melatonin is involved in preventing tumor initiation, promotion, and progression. The anticarcinogenic effect of melatonin on neoplastic cells relies on its antioxidant, immunostimulating, and apoptotic properties. Melatonin's oncostatic actions include the direct augmentation of natural killer (NK) cell activity, which increases immunosurveillance, as well as the stimulation of cytokine production, for example, of interleukin (IL)-2, IL-6, IL-12, and interferon (IFN)-γ. In addition to its direct oncostatic action, melatonin protects hematopoietic precursors from the toxic effect of anticancer chemotherapeutic drugs. Melatonin secretion is impaired in patients suffering from breast cancer, endometrial cancer, or colorectal cancer. The increased incidence of breast cancer and colorectal cancer seen in nurses and other night shift workers suggests a possible link between diminished secretion of melatonin and increased exposure to light during nighttime. The physiological surge of melatonin at night is thus considered a "natural restraint" on tumor initiation, promotion, and progression.
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Melatonin's antineoplastic activity has been explored in both in vivo and in vitro models of carcinogenesis. [11] [12] [13] In addition to its action as a free radical scavenger, melatonin exerts its anticarcinogenic effect by affecting gene expression at physiological levels and through immunomodulatory 14 and antiapoptotic effects. Furthermore, melatonin affects the brain, with actions in the cerebral cortex, the limbic system, and the hypothalamus. 15 Studies of human breast cancer cells have shown that melatonin exerts its anticarcinogenic actions even at physiological concentrations. Melatonin modulates several estrogen-dependent regulatory proteins, suppresses the activity of the estrogen receptor (ER) gene, and arrests the metastatic capacity of cells (for references see Srinivasan et al 16 ).
Melatonin Biosynthesis
In all vertebrates, including humans, melatonin is synthesized primarily by the pineal gland. Melatonin synthesis also occurs in the eye, lymphocytes, skin, gastrointestinal tract, and bone marrow, as well as in other locations. However, unlike melatonin derived from the pineal gland, melatonin produced by these other tissues is not released into blood in significant amounts; rather it functions locally as an autocrine or paracrine signal. 17, 18 Melatonin synthesis starts from the amino acid tryptophan, which is converted into 5-hydroxytryptophan and then to serotonin. 19 Serotonin is acetylated to N-acetylserotonin by the enzyme arylakylamine-N-acetyltransferase, which was long considered to be the rate-limiting enzyme in melatonin synthesis. N-Acetylserotonin is then converted to melatonin by the enzyme hydroxyindole-O-methyltransferase, which is now recognized as the principal rate-limiting enzyme in melatonin synthesis. 20 Once formed, melatonin is released from the pineal gland into the bloodstream 21 and into the cerebrospinal fluid. 22 Melatonin's half-life in blood is about 30 minutes. Pineal melatonin synthesis exhibits a circadian rhythm with low levels occurring during the daytime and high levels during the night. This circadian pattern persists in most animals regardless of whether they are diurnally or nocturnally active. 23 The circadian rhythm and amplitude of the nocturnal rise of melatonin has been studied in humans, and whereas intraindividual patterns of secretion are fairly predictable, comparisons of secretory patterns between individuals show considerable variation. 24 According to Wetterberg, 25 the melatonin rhythm (synthesis/secretion) is genetically determined, an opinion that has received support from studies in siblings. 26 Melatonin production gradually declines with advancing age and melatonin levels are reported to be low in elderly individuals. 27, 28 Some studies, however, have produced findings that are not supportive of this generalization. It has been reported, for instance, that in the age group of 70 to 90 years, 33% of individuals exhibited normal daytime melatonin levels whereas 53% exhibited decreased levels. 29 It is possible that other factors besides age per se may be responsible for these findings and that it is important to look at the total mix of psychological, medical, and lifestyle changes which may cause reductions in melatonin production in the elderly. Epidemiological surveys have shown, for instance, that among healthy older people there are few reports of sleep disturbance, and that they sleep as well as younger subjects, thus implying that in some elderly individuals the capacity for endogenous melatonin production is well preserved. 30, 31 It has been suggested that other age-associated factors such as chronic disease, physical disability, depressed mood, poor perceived health, widowhood, and use of sedatives are possible causal factors for the incident sleep disturbances and thus for circadian rhythm disruption that are seen in the elderly.
Melatonin Metabolism
Circulating melatonin is metabolized mainly in the liver where it is first hydroxylated in the C6 position by cytochrome P 450 mono-oxygenases (isoenzymes CYP1A2, CYP1A1, and to a lesser extent CYP1B1) and thereafter conjugated with sulfate to be excreted as 6-sulfatoxymelatonin. 23 Melatonin can be metabolized nonenzymatically in all cells and also extracellularly by free radicals and other oxidants ( Figure 1 ). It is converted into cyclic-3-hydroxy melatonin when it directly scavenges 2 hydroxyl radicals. In the brain, N 1 -acetyl-N 2 -formyl-5-methoxykynuramine (AFMK) has been identified as one of melatonin's metabolites. AFMK appears to be the central metabolite of melatonin oxidation in nonhepatic tissues. 9 It should be noted that the kynuric pathway of melatonin metabolism includes a series of radical scavengers with the possible sequence of melatonin → cyclic 3-hydroxymelatonin → AFMK → AMK (AMK = N 1acetyl-5-methoxykynuramine). In the metabolic process from melatonin to AFMK, up to 4 free radicals can be consumed ( Figure 1 ). AFMK formation from melatonin has several different pathways with multiple steps, characteristics that have led to the suggestion that AFMK is the primitive and primary metabolite of melatonin. 9
Regulation of Melatonin Synthesis and Release
The light/dark (LD) cycle regulates pineal melatonin synthesis via the retinohypothalamic tract (RHT), which projects from the retina to the suprachiasmatic nucleus (SCN), the major circadian oscillator in the brain. 32 In all organisms melatonin levels are higher at night than during the day. It is for this reason that the nocturnal melatonin profile is regarded as a reliable marker of the endogenous circadian time keeping system in humans. 33 The circadian rhythm of melatonin is endogenously driven and can be significantly impaired by lesions of the SCN. 34 Special photoreceptive retinal ganglion cells that contain melanopsin are involved in the RHT. 35 Fibers from the SCN pass through the paraventricular nucleus, medial forebrain bundle, and reticular formation and terminate on intermediolateral horn cells of the spinal cord. From there, preganglionic fibers project to the superior cervical ganglion (SCG). SCG postganglionic neurons give rise to fibers that innervate the pineal gland and regulate melatonin synthesis by releasing norepinephrine (NE). 36 NE released during the night binds to β-adrenergic receptors on pinealocytes and activates the adenyl cyclase/cyclic adenosine monophosphate (cAMP) mechanism. This in turn activates the synthesis of melatonin. 37 During the light phase of the daily photoperiod, the neurons in the SCN are highly activated. This activity inhibits NE release from the sympathetic fibers that supply the pineal gland and hence melatonin production is suppressed. At night the SCN activity is inhibited and pineal melatonin synthesis is stimulated due to rise in NE secretion. 37
Melatonin Receptors
Melatonin exerts many of its physiological effects by acting through MT 1 and MT 2 melatonin receptors. 38 These receptors, which belong to the superfamily of G-protein coupled receptors and are associated with 7 transmembrane domains, have inhibitory effects on adenyl cyclase. In addition, MT 1 receptors activate protein kinase C-β, whereas MT 2 receptors inhibit the guanylate cyclase pathway 39 and stimulate protein kinase C. 40 MT 1 receptors are expressed broadly in the body but particularly in the brain and account for several effects of melatonin in the brain. 38 In the SCN, both MT 1 and MT 2 receptors are involved in regulating circadian rhythms. 40 The antitumor effect of melatonin in hepatomas has been shown to correlate with MT 1 /MT 2 -dependent inhibition of linoleic acid uptake. 41 Melatonin also binds to calmodulin (CaM) 42 and to tubulin as well as to nuclear receptors of the retinoic acid receptor (ROR) family, RORα1, RORα2, and RZRβ. 43 Melatonin has been shown to influence intracellular CaM distribution, which in turn inhibits cell cycle progression. 42
Melatonin and Breast Cancer
Breast cancer is one of the most frequently occurring cancers among women, and one of the leading causes of death among women aged 40 to 55 years. 44 Risk factors for breast cancer are numerous and include age, genetic makeup, reproductive factors, and ionizing radiation. 45 The role of estrogens has been implicated as a main factor in the development and progression of breast cancer. 46 In recent years, evidence from a number of studies has led to the hypothesis that the increased risk for breast cancer among women involved in night shift work is due to the light-induced inhibition of melatonin secretion. [47] [48] [49] [50] [51] [52] Compared with those working in other professions, women working at night as nurses, 53 flight attendants, 54, 55 or night workers show a significantly greater risk for breast cancer. In a survey carried out in India, women with advanced breast cancer were found to have lower urinary levels of melatonin when compared with controls. 56 This has also been supported by other studies where low serum melatonin concentration and urinary 6 sulfatoxymelatonin levels have been found in women with ER-positive breast cancer. 57, 58 Not all studies have supported this association however, and in one investigation no significant differences were found between 127 breast cancer patients and 353 control subjects in terms of excretion of 6-sulfatoxymelatonin, a major melatonin metabolite. 59
Light at Night and Breast Cancer
A number of investigators have reported an inverse relationship between the incidence of breast cancer and the degree of sightedness, with totally blind women having the lowest incidence of the disease, has been reported by number of investigators. 50, 60, 61 Also, compared with controls, a 40% lower risk for breast cancer has been found among women with reduced sightedness. 50 It has been suggested that the increased risk of breast cancer in industrialized countries is partly due to the increased exposure to light at night 62, 63 with the inhibition of the nocturnal rise in melatonin it entails. 64, 65 It has also been hypothesized that the reduction of melatonin levels following repeated nocturnal exposure to light, as this occurs in women engaged in night-shift work, can result in higher rates of breast cancer development and proliferation. 16, 66 The light-melatonin-breast cancer hypothesis has been supported by experimental studies conducted on athymic female rats in which human breast cancer tissue were transplanted. After being placed under 12L:12D (intact melatonin signal) for 2 weeks, the rats that were exposed to a constant light (300 lux) environment exhibited a 7-fold increase of tumor growth when compared with rats that remained in a normal LD cycle. 67 There was an augmented uptake of linoleic acid and of its metabolism to 1,3-hydroxyoctadecadienoic acid in rats kept under constant illumination. This accelerated rate of linoleic acid metabolism was attributed to the suppression of the circadian melatonin signal which normally inhibits linoleic acid uptake at nighttime. 67 To further support this, venous blood samples were collected from healthy, premenopausal women volunteers during either daytime, nighttime, or nighttime after 90 minutes of exposure to bright light. 41 Compared with tumors perfused with daytime collected melatonin-deficient blood, human breast cancer xenografts and rat hepatomas perfused in situ, with nocturnal, physiologically melatoninrich blood collected during the night, exhibited markedly suppressed proliferative activity and linoleic acid uptake/metabolism. Tumors perfused with melatonindeficient blood collected following ocular exposure to light at night exhibited the daytime pattern of high tumor proliferative activity. 41 These studies are relevant for explaining the increased breast cancer risk in women who are night-shift workers.
Mechanism of Melatonin's Oncostatic Effect on Breast Cancer
A relationship linking pineal gland and breast cancer was first proposed by Cohen et al 68 in 1978, who suggested that a decrease of pineal function with a consequent reduction of melatonin secretion could cause hyperestrogenism, a condition which in itself is known to promote breast cancer development. Melatonin is oncostatic and antiproliferative in breast cancer. 69 Studies using MCF-7 human breast cancer cells demonstrated that physiological concentrations of melatonin have a direct antihormone effect on estradiol-induced cell proliferation. 70, 71 In the presence of either normal serum or estradiol melatonin delays or blocks the progression of cells from G0-G1 into S phase. 71 At nanomolar concentrations melatonin increases the expression of p53 and p21WAFI proteins participating in apoptosis. 72 Melatonin not only reduces MCF-7 cell proliferation but also blocks estradiolinduced invasion capacity of cancer cells. 73 It must be noted that there is convincing evidence in vivo indicating that melatonin's anticancer effect on human breast cancer xenografts is exerted primarily via MT 1 /MT 2 -dependent inhibition of both signal transduction activity and linoleic acid uptake and metabolism. 41 A possible mechanism through which melatonin interacts with estrogens has been proposed. 74 It has been suggested that cAMP intracellular concentrations are modulated by cross-talk between melatonin and estrogen pathways. 75 In MCF-7 cells, estrogens activate adenyl cyclase mechanisms through modulation of either cytoplasmic or cell membrane bound regulatory proteins and cAMP synergizes with the effect of steroids on gene expression in enhancing ER-mediated transcription. 76 Melatonin inhibits adenyl cyclase activity and lowers cAMP concentration through its action on membrane bound MT 1 receptor. 77 Melatonin decreases ERα mRNA and protein levels. [78] [79] [80] At doses of 10 −8 M and 10 −6 M melatonin has been shown to reduce forskolin-induced intracellular cAMP by 57% and 55%, respectively, in MCF-7 human breast cancer cells. This has been suggested as one of the possible mechanisms by which melatonin exerts its antiproliferative and estradiol-inhibitory effect on breast cancer cells. 75 MT 1 melatonin receptors have been shown to mediate the growth inhibitory effects 81 and gene modulatory effects of melatonin in breast tumor cells. 82 Melatonin has also been shown to block the binding of the estradiol-ER complex to ERE in vitro. 83 CaM is a potential candidate for mediating the antiestrogenic actions of melatonin. 83 The association of CaM with estradiol-ER complex facilitates its binding, showing thereby that CaM acts as a modulator of the transcriptional activity of ER. It has been demonstrated that ERα but not ERβ interacts with CaM. 84 By acting as a CaM antagonist, melatonin induces conformational changes in the ERα-CaM complex thereby impairing the binding of E 2 -ERα-CaM complex to DNA. This action, by preventing the ERα-dependent transcription seems to be specific for melatonin and may account for melatonin's antitumor effect in breast cancer. 85 The ratio of ERβ to ERα in the MCF-7 human breast cancer cells determines cells' sensitivity to melatonin. 85 This study revealed that melatonin could be of therapeutic value in tumors with high ERα/ERβ ratio. Melatonin also reduces aromatase enzymatic activity in MCF-7 cells with peak reduction occurring at a 1 nM concentration. 86 This is significant as aromatase is a key enzyme in the conversion of androgens to estrogens, which account for breast cancer in postmenopausal women. This inhibitory effect of melatonin on aromatase activity has been demonstrated in vivo in 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in rats. 87 Although the results on breast cancer cells strongly support the involvement of melatonin receptors and physiological amounts of melatonin in the disease, other alternatives must be considered. There are several mechanisms by which melatonin, at greater than physiological concentrations, can exert its oncostatic actions: (a) by its direct proapoptotic, gene-mediated, actions on tumor cells; (b) by its antioxidant actions; (c) by reducing the uptake of key factors for tumor growth and tumor growth signaling molecules (eg, linoleic acid); and (d) by enhancing immune mechanisms in the body 17, 88, 89 (Figure 2 ).
Melatonin in Endometrial and Ovarian Cancer
Endometrial carcinoma is the most common malignant neoplasm of the female genital tract. Although the pathogenesis of this malignancy is not well understood, melatonin deficiency has been viewed as one of the possible factors due to its antiestrogenic properties. 90 Studies conducted on human ovarian cells (BG-1 cell line) in vitro have shown that melatonin (at concentrations of 10 −5 to 10 −10 M) decreased proliferation of these cells by more than 20%. 91 A nonhomogeneous response to melatonin was found in ovarian carcinoma cell cultures of different cell lines. Cells of one tumor line were inhibited by 90% at a melatonin concentration of 10 −8 M , whereas cells from a second tumor showed growth inhibition by 30%. 92 In another study, 10 −9 M melatonin exerted antiproliferative effect in OVCAR-3 cell lines. 93 Studies conducted in ovarian carcinoma patients did not show any significant differences between melatonin secretion levels in affected individuals when compared with controls. 94 Reduced levels of melatonin secretion have been reported in patients with endometrial cancer. 95 It has been suggested that individual differences are involved in tumor growth modulation and sensitivity to melatonin. 94
Melatonin and Prostate Cancer
The inhibitory effect of melatonin on androgen-sensitive prostate tumors was first demonstrated by using the transplantable Dunning (R3327) prostatic tumor in Copenhagen Fisher male rats. 96 In these animals, late afternoon injections of melatonin significantly inhibited the growth of androgen-sensitive prostatic tumors. The mechanism through which melatonin induces tumor suppression in prostate cells was then studied. Both melatonin and its analog 2-iodomelatonin attenuate epidermal growth facto (EGF)-stimulated cyclin D1 levels and cell proliferation in human LNCaP prostate cancer cells. 97 Melatonin had no effect on androgen-insensitive prostate cancer cell proliferation (DU145 and PC-3 cells) in which the MT 1 receptor mediated signal transduction was defective. 98 Melatonin inhibited the proliferation of hormone-dependent LNCaP prostate cancer cells partly through MT 1 receptor activation both in vitro and in vivo as shown in the nude mice xenograft model. 97 The effect of melatonin on melatonin receptor expression and levels of prostate serum antigen (PSA) was evaluated in prostate cancer patients by examining cancer tissue biopsy and blood serum. MT 1 melatonin receptors were expressed in prostate tumors. Based on serum PSA measurements, it was shown that administration of melatonin (5 mg/day at 20:00 hours) induced stabilization of prostate cancer disease, thus suggesting that melatonin had oncostatic action in prostate cancer patients. 97 Melatonin has been shown to reduce prostate cancer cell number and stop cell cycle progression in both androgendependent LNCaP cells and androgen independent PC3 cells. These effects were not mediated by membrane melatonin receptors and did not involve protein kinase A (PKA) activation. 99 Epidemiological studies have revealed that, compared with the normal population, the incidence of prostate cancer in men with reduced sightedness (and presumably a higher melatonin secretion) is low, although the decreases in cancer incidence were not as profound as those that have been observed for women with breast cancer who also have reduced sightedness. 50
Melatonin in Colorectal Carcinoma
Colorectal cancer is one of the leading types of cancers of the gastrointestinal tract. It is predicted that the prevalence of colorectal cancer will increase in the general population from 0.36% to 0.46% between the years 2000 and 2020. 100 Interest in the possible role of melatonin in colorectal cancer increased following the identification of melatonin binding sites in human colon tissue from patients with carcinoma of the rectum or colon. 125 I-melatonin binding sites were identified in the mucosa/submucosa of the human colon and radioimmunoassay revealed melatonin concentration of 467 ± 99 pg/g human colon. 101 Daytime melatonin concentration in the colon of patients with colorectal carcinoma was 3147 ± 87.8 pg/g tissue. 101 A greater peak amplitude of melatonin rhythm and elevated nocturnal plasma melatonin concentration was also found in patients with colorectal carcinoma. 102 It has been noted that high concentrations of melatonin in the colon stimulate the immune system, enhance free radical scavenging action, and increase levels of fatty acid uptake and metabolism, and it has thus been suggested that melatonin may play an important protective role against the development of colorectal carcinoma.
Consistent with the findings for breast cancer, that is, that nocturnal lighting suppresses melatonin production, being employed on a rotating shift at least 3 nights per month for more than 15 years has been found to significantly increase the risk of colorectal cancer in female nurses. 103 Further confirmation of a possible association between reduced melatonin output and cancer development was provided in a study of melatonin levels in 12 female and 21 male patients with colorectal carcinoma. 104 Compared with 28 healthy age-matched controls, the cancer patients showed significant decrements in the peak amplitude of melatonin secretion as well as a reduction in overall melatonin output. 104 The effect of melatonin on inhibition of colon carcinoma cell growth was studied in CT-26 cells, a murine colon carcinoma-derived cell line. 105 Although melatonin had no effect on cell growth at low doses, a statistically significant and progressive suppression of DNA synthesis was found as melatonin doses increased (the percentage of inhibition being 1 mM, 22%; 2 mM, 25%; 3 mM, 47%). 105 Inasmuch as no receptors were involved in the cell line selected, it was concluded that melatonin exerted its anti-proliferative action through a nonhormonedependent mechanism. In another study the oncostatic effect of melatonin on colon cancer was demonstrated to be mediated through MT 2 receptors and through its binding to nuclear RZR/RORα receptor. 106 CGP 55644, an antagonist of the nuclear RZR/RORα receptor, diminished the oncostatic effect of melatonin on murine colon.
The effect of the simultaneous administration of melatonin and the cytotoxic drug CPT-11 was evaluated in 30 patients with metastatic colorectal carcinoma. 107 It was found that coadministration of melatonin (20 mg/day at bedtime) with CPT-11 was more effective in controlling the disease than administration of CPT-11 alone. These findings support the inference that melatonin play an important adjunctive role in enhancing the effect of chemotherapy in colorectal carcinoma. At 1 mM concentration, melatonin potentiated the flavone-induced apoptosis in HT-29 human colon cancer cells. By increasing the level of oxidizable substrates that can be incorporated into mitochondria in the presence of flavone, melatonin (1 mM concentration) has been shown to potentiate flavoneinduced apoptosis in HT-29 human colon cancer cells. 108
Melatonin in Hepatocarcinoma and Other Cancers of the Digestive Tract
In rat hepatoma 7288CTC, 13-(S)-hydroxyoctadecadienoic acid (13-HODE), formed from linoleic acid by lipoxygenase activity, was identified as the mitogen responsible for linoleic-dependent growth in this tumor. 109 Blask et al 110 demonstrated conclusively that a major mechanism by which physiological and pharmacological blood levels of melatonin inhibits rat hepatoma 7288CTC growth is via a melatonin receptor-mediated suppression of tumor linoleic acid uptake and its metabolism to 13-HODE.
As the mitogenic signal for linoleic acid-dependent tumor growth, 13-HODE enhances EGF responsive mitogenesis through EGF receptor autophosphorylation and tyrosine phosphorylation of key downstream signal transduction proteins such as mitogen-activated protein kinases (MEK and ERK1/2). The proposed steps for the signaling pathway leading to inhibition of linoleic acid-dependent growth by melatonin in hepatoma 7288CTC include melatonin binding to inhibitory G-protein coupled receptors together with reductions in adenylyl cyclase activity, intratumor cAMP levels, fatty acid uptake, 13-HODE formation, phosphorylation of ERK1/2, thymidine incorporation, and growth). 110 N-Nitrosodiethylamine (NDEA) is a potent carcinogenic agent that induces liver cancer. In a recent study performed to evaluate the chemopreventive function of melatonin in this experimental model, Wistar male rats received a single intraperitoneal injection of NDEA or vehicle followed by weekly subcutaneous injections of carbon tetrachloride or vehicle for 6 weeks. Melatonin (5 mg/kg body weight) or its vehicle (0.5 mL saline) was given intraperitoneally on a daily basis 2 hours before lights off for 20 weeks. 111 At the end of this period the rats were sacrificed and liver and blood samples were taken for histological and biochemical studies. NDEA administration inhibited body weight, produced macroscopically and microscopically detectable liver tumors and increased levels of plasma aspartate transaminase, alanine transaminase, and α-fetoprotein. NDEA treatment decreased the levels of liver thiobarbituric acid reactive substances and the activity of catalase and superoxide dismutase. The treatment increased the levels of reduced glutathione in the liver and also increased glutathione peroxidase and glutathione S-transferase activities. Melatonin administration significantly curtailed tumor development and counteracted all the biochemical effects, presumably via its direct and indirect antioxidant effects. 111 In a study conducted on 35 patients (colorectal cancer = 14, gastric cancer = 8, hepatic carcinoma = 6, pancreatic adenocarcinoma = 7), IL-2 and melatonin were administered simultaneously. 112 Melatonin was given orally at a daily dose of 50 mg starting 7 days before IL-2, which was given simultaneously at a dose of 3 × 10 6 IU/day at 20:00 hours for 6 days a week for 4 weeks, which corresponds to one cycle of immunotherapy. Complete response was achieved in 2 patients (gastric cancer = 1 and hepatic carcinoma = 1). Partial response was shown in 6 other patients (gastric cancer = 2, hepatic carcinoma = 2, colon cancer = 1, pancreatic cancer = 1). The overall response rate was 8/35 (23%). The authors concluded from this study that a low dose of IL-2 plus melatonin can be well tolerated and thus may potentially be an effective therapy for advanced tumors of the digestive tract. 112 In another study of 100 patients with inoperable advanced primary hepatocellular carcinoma, transcatheter arterial chemoembolization (TACE) was used alone or in combination with melatonin. 113 The effectiveness rates of TACE or TACE + melatonin were 16% and 28%, respectively. The survival rate of 0.5, 1, and 2 years in the TACE group was 82%, 54%, and 26%, respectively, whereas in the TACE + melatonin group it was 100%, 68%, and 40%, respectively. An elevation of IL-2 level was noted in the patients treated in combination with melatonin, thus showing that melatonin's immunoenhancing function contributed to a greater percentage of the therapeutic response in this group of patients. 113
Melatonin in Melanoma
Melatonin protects human skin against ultraviolet (UV) radiation 114 and X-rays. 115 The radioprotective action of melatonin has been attributed mainly to its ability to scavenge free radicals and to stimulate antioxidative enzymes. 116, 117 Melatonin has also an oncostatic effect against melanomas and tumors of epithelial origin. Melatonin's antiproliferative effect has been demonstrated in B16 murine melanoma cells where it was found to be dose dependent with higher concentrations being more inhibitory than the lower ones. 118 The effect of melatonin ranges from moderately inhibitory (oncostatic) to highly inhibitory to lethal (oncotoxic). It was reported that at low concentrations (2 to 77 pg/cell) melatonin did not significantly affect the cell number, but at intermediate concentrations (1936 to 2003 pg/cell) a moderate inhibitory effect of ≥50% in comparison with control values was shown. At higher concentrations (7743 to 19 356 pg/cell) melatonin caused >50% drop in the cell number. The most striking finding was that at the highest concentration there was total elimination of cells by day 5 of the study. Such an effect of melatonin has been attributed to its direct effect and not to a receptor-mediated cascade of reactions. 118 The presence of high-affinity melatonin binding sites in SK-Mel 28 human melanoma cells has been reported. In these cells, the use of luzindole, a selective blocker for MT 2 receptors reversed the antiproliferative and melanogenic effect of melatonin. 119 In cultured human uveal melanoma cells, melatonin inhibited growth in a dose dependent manner in the range of concentrations from 0.1 to 10 nM. 120 In another study, the growth inhibitory effect of melatonin was demonstrated at a concentration of 2 nM, the physiological concentration found in aqueous humor; the growth inhibiting effect of melatonin on uveal melanoma cells was shown to be related to activation of MT 1 melatonin receptors. 121 In addition, the antiproliferative effect of melatonin was attributed to the stimulatory action on antioxidative enzyme synthesis. 122 High daytime serum melatonin levels (9.7 to 20.9 pg/mL) was reported in patients with melanoma as compared with normal individuals (1.4 to 2.1 pg/mL). 123 High melatonin levels were reported in patients with choroidal melanoma where melatonin levels decreased following enucleation. 124 The increase of melatonin levels seen in these patients was suggested as a compensatory mechanism for arresting the cancerous growth. 124
Melatonin's Antioxidative Action in Neoplastic Disease
ROS generation is a major factor involved in all steps of carcinogenesis, including initiation, promotion, and progression. 7, 125 Oxidant-antioxidant balance affects the rate of cell proliferation and tumor cells generally display low levels of lipid peroxidation, which in turn can stimulate cell division and promote tumor growth. 126 Oxidative stress-induced free radical damage of DNA has been implicated as one of the main contributing factors for the development of cancerous growth. Superoxide radicals (O 2 -) that are generated in the body during oxidative reactions react with hydrogen peroxide (H 2 O 2 ) and generate highly reactive ⋅ OH hydroxyl radicals through fenton reactions that require the presence of a ferrous ion. Hydroxyl radicals damage all cellular components such as lipids, proteins, and DNA molecules. 7, 125 Free radicals are released in a number of situations. Exposure of living cells to ionizing radiation results in free radical generation and oxidative stress. 127 Ionizing and UV radiation are carcinogenic mainly through the induction of ROS. Melatonin has been shown to be protective against oxidative damage caused by ionizing radiation. 128 Ionizing radiation has damaging effects that are both direct and indirect. The indirect effect (∼70%) is due to its interaction with water molecules, which results in the production of highly reactive free radicals such as ⋅ OH which interact with subcellular structures. Melatonin is considered an effective radioprotective agent and this property is due mainly to its free radical scavenging activity and its indirect antioxidant actions. 129 In phase II clinical trials, the protective effects of melatonin (20 mg) were tested in a study of cancer patients undergoing whole-brain radiotherapy treatment for brain metastases, as well as in a variety of other cancer types. 130 Melatonin when used either alone or in combination with standard radiotherapy, and/or chemotherapy, has shown significant beneficial effects in the treatment of wide variety of human cancers, including cancers of the brain, breast, colorectal, hematologic, lung, liver, kidney, and pancreas. It helped in amelioration of myelotoxicity, lymphocytopenia, stabilization of the disease and in some cases, even regression of the disease. 130 The ability of melatonin to scavenge free radicals has been suggested as the main mechanism by which melatonin exerts its beneficial effects in protecting cells from the harmful effect of ionizing radiation. 129 Aging is associated with increased incidence of neoplastic diseases because of the accumulated molecular damage inflicted by lifetime ROS exposure. Because melatonin production also wanes with age, its deficiency has been suggested as one of the probable causes for increased incidence of cancer cases among the elderly. 131 It is well-known that glutathione exists at high concentration intracellularly and protects cells from free radicals and oxidative stress. The rate-limiting step in the synthesis of reduced glutathione is catalyzed by γ-glutamylcysteine synthase. This enzyme is inhibited by buthionine sulfoximine (BSO), which depletes the intracellular reduced glutathione stores. Making use of this phenomenon experimentally, Blask et al 132 demonstrated that the growth inhibitory effect of melatonin at physiological concentrations (10 −9 M) were abrogated by adding BSO, thus suggesting that melatonin exerts its oncostatic effect through the reduced glutathione pathway.
Melatonin regulates the production of reduced glutathione by stimulating its rate limiting enzyme γglutamylcysteine synthase. 133 This action in turn is essential for reducing the generation of hydrogen peroxide (H 2 O 2 ) and hydroxyl ⋅ OH radicals within the cell. 134 This interaction may explain the oncostatic effect of melatonin on cancer cells transformed by oxidative stress. The recent study on melatonin's chemopreventive function in NDEAinduced liver cancer discussed above shows that melatonin's actions have generalizability across tissue lines.
Melatonin's Effect on Angiogenesis in Cancer
Angiogenesis is an essential step in the development of primary tumors. Endothelin-1 synthesis in blood vessels is considered as one of the main stimulants of angiogenesis in primary tumors. Endothelin-1 directly stimulates endothelial as well as perivascular cells by releasing proangiogenic substances such as vascular endothelial growth factor. 135 These effects are arrested by melatonin which suppresses the formation of endothelin-1 by inhibiting endothelin-converting enzyme-1. 136 Further characterization of this effect may provide insights about the molecular mechanisms by which melatonin causes vacuolization of tumors and will contribute significantly to the understanding of its antitumor effects.
Melatonin Immunoenhancement as a Part of Its Oncostatic Effect
An increasing amount of evidence is now showing that melatonin has important immunoenhancing properties that may be of significant therapeutic value in conditions of stress, neoplastic disease, or infections, where immune system functioning is compromised. [137] [138] [139] [140] These effects are now being studied at the cellular and molecular level.
Immunosurveillance is one of the major mechanisms by which cancerous cells are detected and destroyed and NK cells play an important role in immunosurveillance against neoplastic growth. 141 The decline in immune function with aging has been shown to increase the risk for cancerous growth. 142 Therefore, an understanding of the immune changes in the elderly may provide insights into the complex relationship between immunity and cancer. Decrease in T-cell population, caused by diminished thymopoiesis and increased cytokine production has been shown to underlie the immunosenescence in the elderly. 143 Age-associated decline in melatonin is one of the major factors in immunosenescence. 143 Studies on knockout mice with accelerated aging have shown that nearly 50% of aging mice develop spontaneous lymphomas, lung adenocarcinomas, or sarcomas. 144 Melatonin plays a positive role in enhancing immune function in the elderly and is an effective therapeutic agent in immunocompromised states such as stress, neoplastic diseases or infections. 137, 139, 140, 143 Melatonin's oncostatic effects can be attributed to its stimulatory potential on lymphocytes, monocytes/macrophages, and NK cells. 145 Melatonin enhances the production of IL-1, IL-6, tumor necrosis factor (TNF)-α, and IL-12 from the monocytes 146 and enhances the production of IL-2, IFN-γ and IL-6 from cultured human peripheral blood mononuclear cells. 147 In addition to stimulating the production of several cytokines that regulate immune function, melatonin enhances immune function by directly stimulating polymorphonuclear cells, macrophages, NK cells, and lymphocytes. 148 Inasmuch as human lymphoid cells also synthesize melatonin, this additional source of melatonin helps to regulate the human immune system by acting in an autocrine and paracrine manner. 149, 150 Recently, considerable attention has been focused on the effect of melatonin on CD4 + cells. These cells secrete IFN-γ and TNF-α that activate and regulate the cytotoxic T cell response. Melatonin treatment has been found to augment CD4 + cells in lymph nodes of rats. 151 The Th1 cells directly kill tumor cells by releasing cytokines which activate "death receptors" on the tumor cell surface.
Because NK cells are effective against a variety of tumors, especially leukemias and lymphomas, the regulation of NK cell activity and the enhancement of the cytolytic function of NK cells by melatonin 152 have considerable significance for possible therapeutic applications.
A total of 14 patients with untreatable metastatic melanoma were given melatonin in combination with IL-2 and naltrexone, and they showed increases in the Th-1 response and a concurrent suppression of the Th-2 response, an outcome which is considered beneficial in anticancer treatment. 153 In a related study, melatonin was used in combination with IL-2 and cisplatin. The melatonin administration was found to be most effective inasmuch as it not only suppressed tumor growth (metastatic melanoma) but also enhanced the anticancer cytotoxicity of chemotherapeutic drugs and suppressed significantly their toxicity. 153
Melatonin and Apoptosis in Cancer Cells
The role of melatonin in regulating apoptosis has been examined. Several studies have shown melatonin's antiapoptotic effect in immune cells, mainly through direct and indirect mechanisms. [154] [155] [156] In neuronal cells, melatonin also prevents the amyloid-β-induced apoptosis both in vivo and in vitro (see Srinivasan et al 157 for references). Indeed, in most experimental models of apoptosis in which the oxidative damage to the tissue is the predominant feature, melatonin exerted a considerable antiapoptotic effect.
In contrast, in vitro melatonin has been shown to promote apoptosis in breast and colon cancer cells. Melatonin induced apoptosis on MCF-human breast cancer cells by increasing the expression of p21 and p53 proteins that are related to cell cycle control. 73 In the colon (Colon-38) cell line, both in vitro and in vivo conditions, melatonin suppressed cell proliferation, but the proliferating/apoptotic cell ratio was significantly lower with melatonin treatment indicating that the number of apoptotic cells has increased. 158 This proapoptotic effect of melatonin has been proven further in a study on HT-29 human colon cancer cells, where melatonin potentiated flavoneinduced apoptosis. 108 In that study, induction of apoptosis was assessed by caspase-3-type activity, nuclear fragmentation and chromatin condensation. Flavone alone increased caspase-3-type activity 8-fold and DNA fragmentation by 40%. A combination of flavone and melatonin increased caspase-3-type activity 30-fold and DNA fragmentation by 80%. Melatonin potentiated flavoneinduced apoptosis by enhancing the degree of oxidation of the substrates that could be transported into mitochondria in the presence of flavone. 108 This is a new promising field of study where melatonin's proapoptotic effect on tumor cells may have a wide range of therapeutic applications.
Inhibition of Cancer by Melatonin Through Psychological Mechanisms
There is considerable evidence that cancer promotion and progress are influenced by psychological mechanisms, and further that neural circuits involving cerebral cortex limbic system, hypothalamus, and autonomic nervous system are implicated in these effects. 159 In this context, meditation has been found to be beneficial in treating patients with breast or prostate cancer. 160, 161 In a phenomenon exemplifying the fascinating interface between psyche and soma, the regular practice of meditation has been shown to increase physiological levels of melatonin. 160 Because both melatonin and meditation appear to have similar effects on cancer, it has been suggested that psychological procedures may exert beneficial effect in cancer through their regulation of endogenous melatonin secretion. 15 It is hoped that further studies in this line of research will promote a greater understanding of this potentially important approach to cancer treatment.
Conclusions
Melatonin's oncostatic and antiproliferative effects have been demonstrated in a wide variety of endogenous and environmentally induced cancers. In MCF-7 human breast cancer cells, melatonin has direct antiproliferative effects at physiological concentrations by alleviating the action of estrogen on breast tissue. This effect is mediated through the melatonin MT 1 receptor, CaM interaction with E 2 -ER complex, and inhibition of aromatase activity.
A central mechanism involved in melatonin's antitumor action in vivo in a variety of tumor models, including human breast cancer, human squamous cell head/neck tumors, and rat hepatoma includes inhibition of linoleic acid uptake and metabolism to 13-HODE. Melatonin reduces the proliferation of androgen-dependent and androgen-independent prostate cancer cells by acting partly through MT 1 receptors and also through nonreceptor mechanisms. Melatonin exerts its oncostatic effect on colon cancer cells by acting through both MT 2 receptors and nuclear receptors. In addition to receptor-mediated oncostatic effects, melatonin has been demonstrated to affect tumor development via a number of mechanisms. Apoptosis (as shown in HT-29 human colon cancer cells) may be one of these mechanisms. Melatonin's anticancer effect is also due to its immunoenhancement potential such as promotion of NK cell activity, activation of lymphocytes and monocytes, and secretion of cytokines IL-2, IL-6, IL-12, and IFN-γ. Melatonin also has significant potential as a direct and indirect antioxidant agent as well as acting as a antiangiogenic compound ( Figure 2) .
It is interesting that melatonin has the potential as a safe and effective drug not only for exerting its oncostatic effect in cancer patients but also for improving the general health, vitality, physical functioning, and quality of life in cancer patients. 162 Indeed, melatonin may uniquely fit into the integrative aspects of cancer therapy either as a single agent or in a combinatorial setting with standard cancer therapies.
